Radiographic and clinical assessment of unidirectional porous hydroxyapatite to treat benign bone tumors

Abstract Unidirectional porous hydroxyapatite (UDPHAp) was developed as an excellent scaffold with unidirectional pores oriented in the horizontal direction with interpore connections. The purpose of this study was to assess radiographic changes and clinical outcomes and complications following UDPH...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Toshiyuki Kunisada, Joe Hasei, Tomohiro Fujiwara, Eiji Nakata, Suguru Yokoo, Koji Demiya, Toshifumi Ozaki
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/77ec8dfa9d704794a55513300e26c8b0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:77ec8dfa9d704794a55513300e26c8b0
record_format	dspace
spelling	oai:doaj.org-article:77ec8dfa9d704794a55513300e26c8b02021-12-02T12:33:14ZRadiographic and clinical assessment of unidirectional porous hydroxyapatite to treat benign bone tumors10.1038/s41598-020-78409-92045-2322https://doaj.org/article/77ec8dfa9d704794a55513300e26c8b02020-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-78409-9https://doaj.org/toc/2045-2322Abstract Unidirectional porous hydroxyapatite (UDPHAp) was developed as an excellent scaffold with unidirectional pores oriented in the horizontal direction with interpore connections. The purpose of this study was to assess radiographic changes and clinical outcomes and complications following UDPHAp implantation to treat benign bone tumors. We retrospectively analyzed 44 patients treated with intralesional resection and UDPHAp implantation for benign bone tumors between 2010 and 2015. Clinical and radiographic findings were evaluated postoperatively at regular follow-up visits. The mean follow-up was 49 months. Radiographic changes were classified into five stages based on bone formation in the implanted UDPHAp according to Tamai’s classification. All patients showed excellent bone formation inside and around implanted UDPHAp. Absorption of UDPHAp and bone marrow cavity remodeling was identified in 20 patients at a mean of 17 months postoperatively, and was significantly more common in young patients. Preoperative cortical thinning was completely regenerated in 26 of 31 patients on average 10 months after surgery. There were no cases of delayed wound healing, postoperative infection, or allergic reaction related to implanted UDPHAp. UDPHAp is a useful bone-filling substitute for treating benign bone tumor, and the use of this material has a low complication rate.Toshiyuki KunisadaJoe HaseiTomohiro FujiwaraEiji NakataSuguru YokooKoji DemiyaToshifumi OzakiNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-8 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Toshiyuki Kunisada Joe Hasei Tomohiro Fujiwara Eiji Nakata Suguru Yokoo Koji Demiya Toshifumi Ozaki Radiographic and clinical assessment of unidirectional porous hydroxyapatite to treat benign bone tumors
description	Abstract Unidirectional porous hydroxyapatite (UDPHAp) was developed as an excellent scaffold with unidirectional pores oriented in the horizontal direction with interpore connections. The purpose of this study was to assess radiographic changes and clinical outcomes and complications following UDPHAp implantation to treat benign bone tumors. We retrospectively analyzed 44 patients treated with intralesional resection and UDPHAp implantation for benign bone tumors between 2010 and 2015. Clinical and radiographic findings were evaluated postoperatively at regular follow-up visits. The mean follow-up was 49 months. Radiographic changes were classified into five stages based on bone formation in the implanted UDPHAp according to Tamai’s classification. All patients showed excellent bone formation inside and around implanted UDPHAp. Absorption of UDPHAp and bone marrow cavity remodeling was identified in 20 patients at a mean of 17 months postoperatively, and was significantly more common in young patients. Preoperative cortical thinning was completely regenerated in 26 of 31 patients on average 10 months after surgery. There were no cases of delayed wound healing, postoperative infection, or allergic reaction related to implanted UDPHAp. UDPHAp is a useful bone-filling substitute for treating benign bone tumor, and the use of this material has a low complication rate.
format	article
author	Toshiyuki Kunisada Joe Hasei Tomohiro Fujiwara Eiji Nakata Suguru Yokoo Koji Demiya Toshifumi Ozaki
author_facet	Toshiyuki Kunisada Joe Hasei Tomohiro Fujiwara Eiji Nakata Suguru Yokoo Koji Demiya Toshifumi Ozaki
author_sort	Toshiyuki Kunisada
title	Radiographic and clinical assessment of unidirectional porous hydroxyapatite to treat benign bone tumors
title_short	Radiographic and clinical assessment of unidirectional porous hydroxyapatite to treat benign bone tumors
title_full	Radiographic and clinical assessment of unidirectional porous hydroxyapatite to treat benign bone tumors
title_fullStr	Radiographic and clinical assessment of unidirectional porous hydroxyapatite to treat benign bone tumors
title_full_unstemmed	Radiographic and clinical assessment of unidirectional porous hydroxyapatite to treat benign bone tumors
title_sort	radiographic and clinical assessment of unidirectional porous hydroxyapatite to treat benign bone tumors
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/77ec8dfa9d704794a55513300e26c8b0
work_keys_str_mv	AT toshiyukikunisada radiographicandclinicalassessmentofunidirectionalporoushydroxyapatitetotreatbenignbonetumors AT joehasei radiographicandclinicalassessmentofunidirectionalporoushydroxyapatitetotreatbenignbonetumors AT tomohirofujiwara radiographicandclinicalassessmentofunidirectionalporoushydroxyapatitetotreatbenignbonetumors AT eijinakata radiographicandclinicalassessmentofunidirectionalporoushydroxyapatitetotreatbenignbonetumors AT suguruyokoo radiographicandclinicalassessmentofunidirectionalporoushydroxyapatitetotreatbenignbonetumors AT kojidemiya radiographicandclinicalassessmentofunidirectionalporoushydroxyapatitetotreatbenignbonetumors AT toshifumiozaki radiographicandclinicalassessmentofunidirectionalporoushydroxyapatitetotreatbenignbonetumors
_version_	1718393865794224128

Radiographic and clinical assessment of unidirectional porous hydroxyapatite to treat benign bone tumors

Ejemplares similares